Back to top
more

ADC Therapeutics (ADCT)

(Delayed Data from NYSE)

$3.15 USD

3.15
363,661

-0.03 (-0.94%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $3.15 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -31.82% and 44.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of 100% and 15.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update

Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.

Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line

Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.

Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.

Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View

Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.

Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus

Editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide updates by the end of the year. The stock of the company rises about 6% on Wednesday.

Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates

Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance

Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.

Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up

Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.

Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.

Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues

Esperion's (ESPR) second-quarter earnings and revenues beat estimates. The stock surged 7.64% on Tuesday.

Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues

Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

ImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any product sales guidance for Elahere for 2023.

Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates

Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.

Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates

Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results

Bayer (BAYRY) lowers its full-year financial performance guidance for 2023 and reports preliminary earnings results for the second quarter of 2023.

Kodiak (KOD) Down as Late-Stage DME Studies Fail

Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.

Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche

Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.

Roche (RHHBY) SMA Drug Gets Positive CHMP Opinion for Expanded Use

Roche's (RHHBY) Evrysdi gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use in infants under two months with spinal muscular atrophy.

GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?

We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.

Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?

Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.